Otsuka, Shape Ink Potential $1.5B Deal to Develop Eye AAV Gene Therapies
To build its ophthalmology portfolio, Japan’s Otsuka Pharmaceuticals has teamed with RNA editing biotech Shape Therapeutics to develop adeno-associated virus gene therapies for ocular diseases.
Francois Vigneault Toshiki Sudo Sumitomo Pharma Japan Otsuka Pharmaceuticals On Osaka Research Center Otsuka Pharmaceuticals
Source: biospace.com